State Street’s Inozyme Pharma INZY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-331,772
| Closed | -$1.33M | – | 4333 |
|
|
2025
Q2 | $1.33M | Sell |
331,772
-665,333
| -67% | -$1.65M | ﹤0.01% | 3427 |
|
|
2025
Q1 | $907K | Sell |
997,105
-10,350
| -1% | -$14.3K | ﹤0.01% | 3451 |
|
|
2024
Q4 | $2.79M | Sell |
1,007,455
-42,965
| -4% | -$163K | ﹤0.01% | 3207 |
|
|
2024
Q3 | $5.49M | Buy |
1,050,420
+50,386
| +5% | +$262K | ﹤0.01% | 2922 |
|
|
2024
Q2 | $4.46M | Buy |
1,000,034
+119,395
| +14% | +$579K | ﹤0.01% | 2977 |
|
|
2024
Q1 | $6.75M | Buy |
880,639
+134,106
| +18% | +$736K | ﹤0.01% | 2798 |
|
|
2023
Q4 | $3.18M | Buy |
746,533
+118,186
| +19% | +$420K | ﹤0.01% | 3146 |
|
|
2023
Q3 | $2.64M | Buy |
628,347
+67,505
| +12% | +$343K | ﹤0.01% | 3208 |
|
|
2023
Q2 | $3.12M | Buy |
560,842
+462,787
| +472% | +$2.74M | ﹤0.01% | 3214 |
|
|
2023
Q1 | $562K | Buy |
98,055
+21,700
| +28% | +$57.3K | ﹤0.01% | 3703 |
|
|
2022
Q4 | $80.2K | Hold |
76,355
| – | – | ﹤0.01% | 4434 |
|
|
2022
Q3 | $205K | Buy |
76,355
+27,300
| +56% | +$98.8K | ﹤0.01% | 4132 |
|
|
2022
Q2 | $234K | Sell |
49,055
-139,950
| -74% | -$609K | ﹤0.01% | 4127 |
|
|
2022
Q1 | $773K | Buy |
189,005
+1,903
| +1% | +$11.2K | ﹤0.01% | 3890 |
|
|
2021
Q4 | $1.28M | Sell |
187,102
-1,165
| -0.6% | -$10.1K | ﹤0.01% | 3756 |
|
|
2021
Q3 | $2.18M | Buy |
188,267
+18,378
| +11% | +$287K | ﹤0.01% | 3588 |
|
|
2021
Q2 | $2.9M | Buy |
169,889
+37,670
| +28% | +$655K | ﹤0.01% | 3478 |
|
|
2021
Q1 | $2.62M | Buy |
132,219
+14,640
| +12% | +$323K | ﹤0.01% | 3324 |
|
|
2020
Q4 | $2.43M | Buy |
117,579
+46,994
| +67% | +$1.12M | ﹤0.01% | 3285 |
|
|
2020
Q3 | $1.86M | Buy |
+70,585
| New | +$1.75M | ﹤0.01% | 3230 |
|
State Street's INZY Position: Q3 2025 in Review
State Street sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 331,772 shares — an estimated $1.33M sold.
State Street first reported a position in INZY in Q3 2020 and held it in 20 quarters. The position peaked at $6.75M in Q1 2024. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.
- State Street reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
- State Street sold 331,772 Inozyme Pharma shares in Q3 2025, an estimated $1.33M.
- State Street first reported a position in Inozyme Pharma in Q3 2020 and held it in 20 quarters.
- State Street's Inozyme Pharma position peaked at $6.75M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.
Based on State Street's 13F filing for Q3 2025, filed 14 Nov 2025.